Press Release Source: Geron Corporation
Geron Announces Conference Call to Discuss Financial Results for the 2006 Third Quarter
Friday October 27, 7:30 am ET
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN - News) will announce its financial results for the three and nine months ended September 30, 2006, on Monday, October 30, 2006, prior to the opening of the equity market. Thomas B. Okarma, Ph.D., M.D., Geron's chief executive officer, and David L. Greenwood, Geron's chief financial officer, will host a conference call for analysts and investors following the announcement at 8 a.m. PST/11 a.m. EST.
Participants can access the conference call live via telephone by dialing 866-831-6267 (U.S.) or 617-213-8857 (international). The passcode is 12545730. A live audio-only Webcast is also available through a link that is posted on the Conferences page in the Investor Relations section of Geron's Website at http://www.geron.com. The audio web broadcast of the conference call will be available for replay through November 30, 2006.
Geron is a Menlo Park, Calif.-based biopharmaceutical company that is developing and intends to commercialize first-in-class therapeutic products for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The products are based on Geron's core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.
Contact:
Noonan Russo
Media:
David Schull, 858-546-4810
david.schull@eurorscg.com
or
Investors:
Sharon Weinstein, 212-845-4271
sharon.weinstein@eurorscg.com
or
at Geron
David L. Greenwood, Chief Financial Officer, 650-473-7765
info@geron.com
--------------------------------------------------------------------------------
Source: Geron Corporation
Geron Announces Conference Call to Discuss Financial Results for the 2006 Third Quarter
Friday October 27, 7:30 am ET
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN - News) will announce its financial results for the three and nine months ended September 30, 2006, on Monday, October 30, 2006, prior to the opening of the equity market. Thomas B. Okarma, Ph.D., M.D., Geron's chief executive officer, and David L. Greenwood, Geron's chief financial officer, will host a conference call for analysts and investors following the announcement at 8 a.m. PST/11 a.m. EST.
Participants can access the conference call live via telephone by dialing 866-831-6267 (U.S.) or 617-213-8857 (international). The passcode is 12545730. A live audio-only Webcast is also available through a link that is posted on the Conferences page in the Investor Relations section of Geron's Website at http://www.geron.com. The audio web broadcast of the conference call will be available for replay through November 30, 2006.
Geron is a Menlo Park, Calif.-based biopharmaceutical company that is developing and intends to commercialize first-in-class therapeutic products for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The products are based on Geron's core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.
Contact:
Noonan Russo
Media:
David Schull, 858-546-4810
david.schull@eurorscg.com
or
Investors:
Sharon Weinstein, 212-845-4271
sharon.weinstein@eurorscg.com
or
at Geron
David L. Greenwood, Chief Financial Officer, 650-473-7765
info@geron.com
--------------------------------------------------------------------------------
Source: Geron Corporation